Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, 06 1997, 1319-1321, Vol 41, No. 6
PE Rolan, AJ Mercer, E Tate, I Benjamin and J Posner
Atovaquone is an antiprotozoal compound with good in vitro stability
against metabolic inactivation. Previous human studies which did not
involve radiolabelling had not accounted for a substantial proportion of
the dose. The possible metabolism of atovaquone in men was examined in a
radiolabelling study involving four healthy male volunteers. Radioactivity
was eliminated almost exclusively via the feces. All radioactivity in
plasma, urine, and feces was accounted for by atovaquone, with no evidence
of metabolites. Radiolabelled atovaquone was administered to a patient with
an indwelling biliary tube after surgery. Biliary radioactivity was
approximately 10- to 40-fold higher than that in plasma and was accounted
for by atovaquone. Atovaquone is not significantly metabolized in humans
but is excreted into bile against a high concentration gradient.
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
Disposition of atovaquone in humans
Department of Clinical Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, United Kingdom.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»